Acute leukaemia in Jehovah's Witnesses. (opens new window)

Bueno J, Zuazu J, Villalba T, Julià A.

Źródło‎: Haematologica 2001;86(2):E02.

Indeks‎: PubMed 11224505

https://www.ncbi.nlm.nih.gov/pubmed/11224505 (opens new window)

Leczenie ostrej białaczki u Świadków Jehowy—opis przypadku i przegląd piśmiennictwa. [Treatment of acute leukemia in Jehovah's Witnesses—a case report and review of the literature.] [Polish, English abstract] (opens new window)

Chojnowski K, Trelinski J.

Źródło‎: Acta Haematol Pol 2007;38(4):479-84.

Indeks‎: EMBASE 2008089811

https://web.archive.org/web/20210506152723/https:/pthit.pl/Acta_Haematologica_Polonica,Ostra_bialaczka_Chemioterapia_Swiadkowie_Jehowy_Przetoczenie_krwi,395.html (opens new window)

Treatment of acute leukaemia in adult Jehovah's Witnesses. (opens new window)

El Chaer F, Ballen KK

Źródło‎: Br J Haematol 2020;190(5):696-707.

Indeks‎: PubMed 31693175

DOI‎: 10.1111/bjh.16284

https://www.ncbi.nlm.nih.gov/pubmed/31693175 (opens new window)

Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (opens new window)

Ford PA, Grant SJ, Mick R, Keck G.

Źródło‎: J Clin Oncol 2015;33(15):1674-9.

Indeks‎: PubMed 25870085

DOI‎: 10.1200/JCO.2014.57.9912

https://www.ncbi.nlm.nih.gov/pubmed/25870085 (opens new window)

Should Jehovah's Witnesses be denied intensive chemotherapy for acute leukemia? (opens new window)

Goldberg SL, Chan CS, Dawkins FW, Mehlman TW, Schechter GP.

Źródło‎: N Engl J Med 1990;322(11):777-8.

Indeks‎: PubMed 2308609

DOI‎: 10.1056/NEJM199003153221115

https://www.ncbi.nlm.nih.gov/pubmed/2308609 (opens new window)

Myeloablative therapy and bone marrow transplantation in Jehovah's Witnesses with malignancies: single center experience. (opens new window)

Mazza P, Prudenzano A, Amurri B, Palazzo G, Pisapia G, Stani L, Pricolo G.

Źródło‎: Bone Marrow Transplant 2003;32(4):433-6.

Indeks‎: PubMed 12900781

DOI‎: 10.1038/sj.bmt.1704179

https://www.ncbi.nlm.nih.gov/pubmed/12900781 (opens new window)

Developing a blood conservation care plan for Jehovah's Witness patients with malignant disease. (opens new window)

Norfolk DR, Wade P, Carter R.

Źródło‎: Presented at the British Society for Haematology 47th Annual Scientific Meeting, Bournemouth [UK] April 2007.

https://www.transfusionguidelines.org/document-library/documents/developing-a-blood-conservation-care-plan-for-jehovah-s-witness-patients-with-malignant-disease/download-file/bbt-JW-Care-Plan-Malignant-Disease-2012.pdf (opens new window)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (opens new window)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Źródło‎: Leuk Lymphoma. 2019;60(9):2324-7.

Indeks‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (opens new window)

Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses. (opens new window)

Riedell PA, Wu M, Collins JM, Gideon JM, Jakubowiak AJ, Kline JP, Kosuri S, Liu H, Smith SM, Bishop MR

Źródło‎: Leuk Lymphoma 2021;62(6):1497-501.

Indeks‎: PubMed 33535838

DOI‎: 10.1080/10428194.2021.1876868

https://www.ncbi.nlm.nih.gov/pubmed/33535838 (opens new window)